Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRANSLATE BIO, INC.

(TBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
19.12(c) 20.21(c) 21.7(c) 21.7(c) 21.39(c) Last
934 042 1 329 829 811 152 537 395 305 805 Volume
+2.91% +5.70% +7.37% 0.00% -1.43% Change
More quotes
Financials (USD)
Sales 2021 111 M - -
Net income 2021 -30,6 M - -
Net cash position 2021 509 M - -
P/E ratio 2021 -43,9x
Yield 2021 -
Sales 2022 148 M - -
Net income 2022 -49,6 M - -
Net cash position 2022 494 M - -
P/E ratio 2022 10,7x
Yield 2022 -
Capitalization 1 609 M 1 609 M -
EV / Sales 2021 9,89x
EV / Sales 2022 7,55x
Nbr of Employees 122
Free-Float 91,0%
More Financials
Company
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or... 
More about the company
Ratings of Translate Bio, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about TRANSLATE BIO, INC.
06/09Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
06/07TRANSLATE BIO  : Reaches $50 Million Milestone Payment Under Sanofi Influenza mR..
MT
06/07TRANSLATE BIO  : Achieves Manufacturing Milestone Related to Influenza mRNA Vacc..
AQ
05/24Translate Bio to Participate in Upcoming Investor Conferences
GL
05/18Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD..
GL
05/17Sanofi-GSK report positive interim results for their COVID-19 shot
RE
05/17Sanofi/GSK report positive interim results for their COVID-19 shot
RE
05/06TRANSLATE BIO  : Management's Discussion and Analysis of Financial Condition and..
AQ
05/06TRANSLATE BIO  : Announces First Quarter 2021 Financial Results and Provides Cor..
AQ
05/06TRANSLATE BIO  : Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
05/05Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
04/28Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Su..
GL
04/28Eczema treatment and vaccines lift Sanofi first quarter results
RE
04/26France's Sanofi to help Moderna manufacture COVID-19 shots
RE
04/26Sanofi to Help Make Moderna Covid-19 Vaccine for U.S.
DJ
More news
News in other languages on TRANSLATE BIO, INC.
05/17CORONAVIRUS : Sanofi va passer à la dernière phase d'essais pour son vaccin
04/26La francesa Sanofi ayudará a Moderna a fabricar vacunas de COVID-19
04/26Sanofi ayudará a fabricar vacuna Covid-19 de Moderna para EEUU
03/23Pfizer va développer de nouveaux vaccins en utilisant l'ARN messager, rapport..
03/16ENFOQUE-Dinero y talento se mueven al sector del ARN mensajero tras éxito con..
More news
Analyst Recommendations on TRANSLATE BIO, INC.
More recommendations
Chart TRANSLATE BIO, INC.
Duration : Period :
Translate Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSLATE BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 24,00 $
Last Close Price 21,39 $
Spread / Highest target 30,9%
Spread / Average Target 12,2%
Spread / Lowest Target -11,2%
EPS Revisions
Managers and Directors
NameTitle
Ronald C. Renaud Chief Executive Officer & Director
E. Rand Sutherland President
Brendan Smith Chief Financial Officer & Head-Corporate Strategy
Daniel S. Lynch Chairman
Ann Barbier Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
TRANSLATE BIO, INC.16.06%1 609
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966